Evidence map›Paper›PMID 41459302›Full record

ArticleOpen forum infectious diseases2026

Antifungal Resistance Surveillance: Insights From National Mycology Reference Centers and Expert Mycology Laboratories.

Alexandre Alanio, P Lewis White, Maiken Cavling Arendrup, Alida Fe Talento, Cecile Torp Andersen, Elizabeth Johnson, Fanny Lanternier, Joseph Meletiadis, Karen M T Aastvad, Lize Cuypers and 7 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alexandre AlanioMycology Department, Institut Pasteur, Université Paris Cité, National Reference Centre for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Paris, France.ORCID https://orcid.org/0000-0001-9726-3082
P Lewis WhitePublic Health Wales Mycology Reference Laboratory and Cardiff University Centre for Trials Research, UHW, Cardiff, United Kingdom.ORCID https://orcid.org/0000-0003-3056-4205
Maiken Cavling ArendrupUnit of Mycology, Statens Serum Institut, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4747-0144
Alida Fe TalentoDepartment of Microbiology, Children's Health Ireland, Dublin, Ireland.ORCID https://orcid.org/0000-0003-1271-2550
Cecile Torp AndersenDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Elizabeth JohnsonUK Health Security Agency National Mycology Reference Laboratory, Southmead Hospital, Bristol, United Kingdom.
Fanny LanternierMycology Department, Institut Pasteur, Université Paris Cité, National Reference Centre for Invasive Mycoses and Antifungals, Translational Mycology Research Group, Paris, France.ORCID https://orcid.org/0000-0003-3800-4683
Joseph MeletiadisClinical Microbiology Laboratory, Attikon University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-8869-1509
Karen M T AastvadUnit of Mycology, Statens Serum Institut, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4651-2904
Lize CuypersDepartment of Laboratory Medicine, National Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-9433-8752
Oliver KurzaiUniversity of Wuerzburg, Institute for Hygiene and Microbiology, Wuerzburg, Germany.
Reinhild StraussDepartment of Federal Ministry for Health, Medical University Vienna, Vienna, Austria.
Riina Rautemaa-RichardsonMycology Reference Centre Manchester, ECMM Centre of Excellence, and Department of Infectious Diseases, Manchester Academic Health Science Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.ORCID https://orcid.org/0000-0002-1071-6040
Sharon ChenCentre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Research and Medical Research, Westmead Hospital, and the University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0002-9983-6603
Paul E VerweijDepartment of Medical Microbiology and Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-8600-9860
Ana Alastruey-IzquierdoMycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.ORCID https://orcid.org/0000-0001-8651-4405
INFORM network and the EFISG-STARs project

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal pathogens and the infections they cause are notoriously understudied and underrepresented in public health surveillance programs. Recent initiatives, such as that of the Joint Programming Initiative on Anti-Microbial Resistance (JPIAMR), recognize these gaps and have supported the development of a fungal surveillance resistance network. The International Fungal Network for One-Health Resistance Surveillance: Antifungal Resistance (INFORM-AFR) network sought to enhance understanding of existing surveillance programs, with the ultimate goal of developing standardized fungal surveillance strategies that enable international comparisons. A survey was conducted involving mycology reference centers or public health institutes (n = 15) from 12 countries, each responsible for nationwide or regional surveillance programs on fungal infections or pathogens. The ongoing programs were heterogenous, not only in terms of the epidemiological focus of surveillance (pathogen vs disease based), but also in relation to the mycological procedures used (identification and antifungal susceptibility testing methods). Funding dedicated to surveillance was variable and often lacked long-term stability, resulting in suboptimal surveillance data in many centers and limiting the generation of accurate and consistent knowledge. With the expanding number of fungal disease cases and increasing reports of antifungal resistance, we strongly advocate for improved integration of fungal infections into nationwide health surveillance programs as well as international standardization.

Indexed as

antifungal drugsepidemiologyfungal infectionresistancesurveillance

Identifiers

PMID41459302
PMCPMC12740717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.